Biotest Facility

Overview

Biotest Facility is a Danish contract research organization (CRO) focused on accelerating biotech and pharmaceutical innovation. The organization integrates state-of-the-art in vivo models with comprehensive analytics and data science, operating as a data-driven partner guiding projects from concept to decision-ready outcomes.

Core Capabilities

In Vivo Models

• Robust rodent models for pharmacology, efficacy, and safety studies
• Study design, execution, and regulatory-ready documentation
• Scalable capacity with focus on quality, reproducibility, and data traceability

Analytical Services and Omics

• Proteomics: targeted panels and discovery approaches for biomarker assessment (including Olink Explore 3072 platform with 3000+ protein biomarkers)
• Transcriptomics and gene expression profiling: qPCR, NanoString, dPCR, RNA-Seq prep and sequencing
• Small-molecule detection and quantification via LC-MS/MS workflows
• Genotyping and targeted SNP panels
• Digital PCR services

Biomarker Discovery and Validation

• Biomarker signature discovery in clinical and preclinical settings
• Biomarker panels aligned with patient cohorts and hospital collaborations
• Protein biomarker analysis related to Oncology, Inflammation, Cardiometabolic, and Neurology

Bioinformatics and Biostatistics

• Data management and integration across platforms
• Customized statistical analysis and result interpretation
• Visualization, reporting, and decision-support

Differentiation

Biotest Facility emphasizes automated workflows, high multiplex levels, time- and cost-efficient planning, and reproducible results. The organization operates under controlled conditions with commitment to highest quality standards. Following integration of BioXpedia assets in 2025, the facility is investing in upgraded in vivo facilities, expanded analytical capacities, and strengthened global outreach.